CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
Olanzapine 10 mg po qhs for 3 days +1 moredrug
Likely dose
Olanzapine 10 mg po qhs for 3 daysfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00741026
NCT00741026N/ACompleted

A Double-blind, Placebo-controlled, Crossover Study Examining the Acute Effects of Olanzapine on Plasma Leptin, Glucose Tolerance and Free Fatty Acids in Healthy Volunteers

Milton S. Hershey Medical Center·interventional·Posted Aug 25, 2008·Updated Jul 14, 2014

In Brief

A clinical study evaluating Olanzapine 10 mg po qhs for 3 days and Placebo for Insulin Resistance and Diabetes Mellitus. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this clinical research study is to examine the acute hormonal and metabolic effects of the drug olanzapine, as well as appetite effects, in healthy volunteers. The hypotheses to be tested are that: (1) Olanzapine rapidly attenuates plasma leptin and (2) rapidly alters glucose tolerance in healthy volunteers. These questions will be answered by having volunteers undergo two glucose tolerance tests in a crossover study design.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 25, 2008
Enrollment StartAug 1, 2008
Primary CompletionDec 1, 2010
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.9 years ago

Interventions

Olanzapine 10 mg po qhs for 3 daysdrug

(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)

Placebodrug

(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)